SAN DIEGO—(BUSINESS WIRE)—April 2, 2007—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD) announced today the filing of a preliminaryprospectus supplement to its effective shelf registration statementpreviously filed with the Securities and Exchange Commission relatingto a proposed underwritten public offering of 5,000,000 shares of itscommon stock. In connection with the offering, ACADIA also plans togrant the underwriters an option to purchase up to 750,000 additionalshares of its common stock. All of the shares are being sold byACADIA.
The book-running managers for the offering are Banc of AmericaSecurities LLC and Lehman Brothers Inc., the co-lead manager isDeutsche Bank Securities Inc., and the co-managers are Piper Jaffray &Co., JMP Securities LLC and Rodman & Renshaw, LLC.
This press release shall not constitute an offer to sell or thesolicitation of an offer to buy these securities, nor shall there beany sale of these securities, in any jurisdiction in which such offer,solicitation or sale would be unlawful prior to registration orqualification under the securities laws of any such jurisdiction. Theoffering of these securities may be made only by means of theprospectus supplement, related prospectus and any supplementalinformation relating to the offering. You may obtain a preliminaryprospectus supplement and prospectus by contacting Banc of AmericaSecurities LLC, Capital Markets (Prospectus Fulfillment) by e-mail todg.prospectus_distribution@bofasecurities.com or by mail to Banc ofAmerica Securities LLC, Capital Markets Operations, 100 West 33rdStreet, 3rd Floor, New York, NY 10001 and Lehman Brothers Inc. bye-mail to qiana.smith@broadridge.com or by fax to (631) 254-7268 or bymail to Lehman Brothers, c/o Qiana Smith, Broadridge, ProspectusFulfillment, 1155 Long Island Avenue, Edgewood, NY 11717.
ACADIA Pharmaceuticals is a biopharmaceutical company with itscorporate headquarters located in San Diego, California and researchand development operations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief FinancialOfficer
858-558-2871
SOURCE: ACADIA Pharmaceuticals Inc.